Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with
Jazz tested a cancer medicine called Ziihera and it worked better than the usual treatment in a big, late-stage study. When a company's new medicine beats the old way, that's a positive sign that doctors might use it—but we have to wait for regulators to approve it first.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.